Most Pharma Companies Get This Wrong About Manufacturing | Axplora

I Built A Billion-Dollar Company, Lost It All... Then Built Another 5 - Robert Wessman

We Just Built a $1.5B Biologics Company… And We're Here to Disrupt the Industry - Joon Chang

How Samsung Biologics Is Redefining CDMO Partnerships - John Gagliardi

From Lab Scientist to Pharma Leader: 40 Years of Scaling and Strategy Insight - Alison Clayton

This CDMO Has an Advantage No One Else Can Replicate - Quotient Sciences

The Hidden Challenges of Biologics Development - Dr. Adriana Kiędzierska-Mencfeld

AI Discovering Medicines Humans Could Never Find: James Field - LabGenius Therapeutics

Why CDMOs Must Scale Smarter - Peter Belden

Building a Pharma Company Is Harder Than You Think - David Stevens

This Model Could Replace Traditional CDMOs - Sarah Stevens

Why Process Control Systems Are Critical for GMP Manufacturing | ISPE GxP Guide Explained

AI Will Fail in Manufacturing Without This - Sam Brooks

Inside DCAT Week: Behind the Scenes with ARTO in New York

Why Most Manufacturing Projects Fail Before Qualification Starts

The European Pharma Contractor Market Is Shifting | ARTO Insights

The Relentless Mindset Behind Scaling a Drug Manufacturing Company | Curapath

How Pharma Actually Sets Global Standards (GAMP Explained)

From First Job to First Deal | Building a Career in Recruitment | ARTO Insights

From Pro Rugby to CDMO Business Development | Lessons in Resilience & Relationships | ARTO Insights

Will the Drug Work? Engineering a New Future for Oncology - BioCortex

How Xellia Is Reshaping Europe’s Antibiotics Market | CEO Michael Kocher

A Single Injection set to Eliminate Cancer? CEO of Candel Therapeutics - Paul Peter Tak

Why 3–5 Year Experience Is the Hardest Hire in Biotech and Pharma | ARTO Insights

The Untold Reality of Scaling Global Pharma Manufacturing - Xellia Pharmaceuticals

Inside Mabion’s Growth Strategy | CEO Gregor Kawaletz on Biosimilars & Biologics

Is AI About to Collapse the Cost of Healthcare — Or Is This Another Tech Bubble? | Edward Kliphuis

Building Trust in Pharma and Biotech Manufacturing Partnerships | Sharp Services

Parkinson’s Breakthrough Could Be Just Around the Corner | BlueRock Therapeutics

How Smart Capital Is Shaping the Future of Biotech - Jonathan Tobin

How Instapill Is Redefining Drug Delivery with FDA-Approved ODT Tech – Ankit Gupta, CEO

Nikhil Thatte On Investing In Best In Class Biotech and Medtech Companies

How Enzene Is Leading the Future of Biologics Manufacturing

Scaling a Legacy CDMO: Inside Pyramid Pharma’s Fill-Finish Expansion

How NodThera’s NLRP3 Marks A New Era for Obesity Treatment

Supporting “N of 1” Therapies: The CDMO Perspective with Raj Puri

How ten23 Became One of Europe’s Fastest-Growing Drug-Product CDMOs

How To Get Investment From Joey Mason | 25 Years In Life Sciences VC

How Do You Successfully Scale and Integrate CDMO Sites After Acquisition?

How Syncona built a $1Billion Dollar NAV Portfolio - Roel Bulthuis

CEO of LEO Pharma Reveals Their IPO Strategy: Christophe Bourdon

Building a High-Impact Biotech Investment Engine - Clare Terlouw

Danniella Brown: Training That Actually Works - ARTO’s Approach to Consultant Success

Megan Hayward: Evolving Recruitment into Strategic Talent Solutions

Is Nuclear Medicine Becoming Next Big Breakthrough in Oncology Treatment? Danielle Meyrick

David Hallett: How to Become Successful in BD Within the CDMO Space

Normunity's Breakthrough Oncology Treatment the World Hasn't Seen Before

How Maxion's KnotBody® Platform Is Changing the Way We Treat the 'Undruggable' - Arndt Schottelius

From Clinic to Billion-Dollar Breakthroughs: Christopher Morabito’s Journey in Biotech

Needle in a Haystack Antibody Unlocking A Fundamental Pathway in Disease Biology: Bhaskar Srivastava

Charlie Jones: Clinical Development Changes Within Immunology

Mara Aspinall: The Former CEO Now Funding the Genomics Revolution

Building Biotech in Saudi Arabia: An Investor’s View

Éoin O'Donoghue: An Evolving Medical Affairs Market & The War For Talent

How a Crack in Equipment Taught Abbas Hussain the Value of Planning Buffers

How Michael Vrijs Defends His Site Against Auditors - Without Saying Too Much

Anna-Louise Webb: Medical Affairs - Future Market, Investment Opportunities and Current Talent

Carsten Jasper: Revolutionising Pharma Compliance with AI, Cleanrooms & Bold Thinking

Jamie Stephens: Clinical Development - Current Market, Investment, Talent and The Future

Simon Adams: Building Organisations That Can Withstand Change